News | October 14, 2024
Indian drug regulator recommends Wockhardt's Miqnaf for treatment of CABP
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
Subscribe To Our Newsletter & Stay Updated
